FTH Faeth Therapeutics, Inc.
Company Updates ·
Faeth reported a net loss of $16.0 million for the quarter ended June 30, 2026, and said topline data from its Phase 2 PIK-201 trial in endometrial cancer are expected by year-end.
Sensei Biotherapeutics closed its acquisition of Faeth Therapeutics on February 17, 2026, and agreed the same day to sell about $200 million of Series B preferred stock. The new investors would hold 54.3% of the company on an as-converted basis, and the lead drug's headline response rate comes from 15 patients.
Nasdaq staff found the stock closed at $1.00 or more for 10 consecutive business days, from June 17, 2025 to July 1, 2025.
Sensei Biotherapeutics told investors on January 7, 2025 that Nasdaq had moved its stock to the Capital Market and given it until July 7, 2025 to lift its share price above $1.00. Its 2023 annual report showed a $34,101 thousand net loss and cash that fell to $13,011 thousand at year end.
Faeth Therapeutics, Inc. is a clinical-stage biotechnology company focused on improving outcomes for cancer patients through multi-node inhibition of critical oncogenic pathways. The filing is made by Sensei Biotherapeutics, Inc., which completed its acquisition of Faeth Therapeutics on February 17, 2026. The lead asset, PIKTOR, is an all-oral combination of serabelisib and sapanisertib that inhibits multiple nodes of the PI3K/AKT/mTOR pathway. It is in development for endometrial and breast cancer. PIKTOR is in an ongoing Phase 2 trial in second-line advanced endometrial cancer, with topline data anticipated by year-end 2026. In May 2026, the company announced that it had dosed the first patient in a Phase 1b trial in HR+/HER2- advanced breast cancer. The acquisition came with $200 million in gross proceeds from a private placement from a syndicate of investors. The company says the PI3K/AKT/mTOR pathway is dysregulated in up to 50% of all solid tumors, and that currently approved therapies each target only a single pathway node.
| Product or program | What it is | Stage |
|---|---|---|
| PIKTOR | All-oral combination of serabelisib and sapanisertib, a multi-node PI3K/AKT/mTOR inhibitor | Phase 2 in endometrial cancer; Phase 1b in breast cancer |
| Line | FY2025 | FY2024 |
|---|---|---|
| Net income (loss) | -$21.1 million | -$30.2 million |
| Cash from operations | -$20.5 million | -$24.7 million |
| Cash and equivalents | $8.7 million | $10.0 million |
| Short-term investments | $12.5 million | $31.3 million |
Our latest story on this, dated Feb 18, 2026: "Sensei Biotherapeutics acquires Faeth Therapeutics, agrees to $200 million private placement". The story links the filing or release it is based on. Read the story.
Faeth Therapeutics, Inc. trades under the ticker FTH on NASDAQ.
Faeth Therapeutics, Inc. is listed on NASDAQ.
The SEC Central Index Key (CIK) for Faeth Therapeutics, Inc. is 1829802. Its filings are on SEC EDGAR.
25,840,425 shares as of 2026-07-30, per the cover page of its 10-Q filed 2026-08-04.
Our directory records Faeth Therapeutics, Inc. under United States.
Our directory classifies Faeth Therapeutics, Inc. as: Biotechnology. This is a directory classification, not a description of the pipeline.
The ISIN recorded for Faeth Therapeutics, Inc. is US81728A2078.
aibio.space lists Faeth Therapeutics, Inc. among 2,820 public biotech companies and publishes its news here as stories appear.
SEC records list its state or country of incorporation as DE.
Faeth Therapeutics, Inc. is a clinical-stage biotechnology company focused on improving outcomes for cancer patients through multi-node inhibition of critical oncogenic pathways. The filing is made by Sensei Biotherapeutics, Inc., which completed its acquisition of Faeth Therapeutics on February 17, 2026.
PIKTOR: All-oral combination of serabelisib and sapanisertib, a multi-node PI3K/AKT/mTOR inhibitor Stage: Phase 2 in endometrial cancer; Phase 1b in breast cancer.
Faeth Therapeutics, Inc. reported a net loss of $21.1 million for the fiscal year ended Dec 31, 2025, and used $20.5 million of cash in operations, per its annual report to the SEC.
$186.4 million in cash and short-term investments at Jun 30, 2026, per its 10-Q.
Our latest story on Faeth Therapeutics, dated Aug 4, 2026: "Faeth Therapeutics reports $186.4 million in cash and securities after Sensei combination". Faeth reported a net loss of $16.0 million for the quarter ended June 30, 2026, and said topline data from its Phase 2 PIK-201 trial in endometrial cancer are expected by year-end. Source.
Reported a financing. SEC Form S-3ASR. Source
Reported the end of a material agreement. SEC Form 8-K (Items 1.02,5.02,5.03,7.01,8.01,9.01). Source
Reported a shareholder vote on a reverse stock split or more authorized shares. SEC Form 8-K (Items 5.02,5.03,5.07,9.01). Source
Reported a merger or acquisition agreement. SEC Form 8-K (Items 1.01,2.01,3.02,5.02,5.03,7.01,9.01). Source
Reported a restructuring, a workforce reduction or a review of strategic alternatives. SEC Form 8-K (Items 7.01,9.01). Source
Reported a notice from its stock exchange about continued listing requirements. SEC Form 8-K (Items 3.01). Source
Reported a reverse stock split. SEC Form 8-K (Items 5.03,9.01). Source
Reported a shareholder vote on a reverse stock split or more authorized shares. SEC Form 8-K (Items 5.07). Source
Reported substantial doubt about its ability to continue as a going concern. SEC Form 10-Q. Source
Asked shareholders to approve a reverse stock split. SEC Form DEF 14A. Source
Asked shareholders to approve a reverse stock split. SEC Form PRE 14A. Source
Reported a notice from its stock exchange about continued listing requirements. SEC Form 8-K (Items 3.01,9.01). Source
Who manages this page This page is managed by aibio.space. The company does not run, edit or pay for this page. News, desk views and Investor Ranks are written and managed independently by aibio.space under our editorial and analytical judgment. Opinion only, not investment advice. How we work · Terms · Request a correction
aibio